ReviewMedical oncology (Northwood, London, England)2014
MicroRNA-21 and multiple myeloma: small molecule and big function.
Review in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- The impact of STAiR18 on multiple myeloma survival rates.Journal of translational medicine · 2025Article
- Effect of adipose tissue on the development of multiple myeloma.Molecular biology reports · 2024Review
- Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment.International journal of molecular sciences · 2024Article
- Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.Cells · 2021Review
- The microRNA miR-19a-3p suppresses cell growth, migration, and invasion in multiple myeloma via the Wnt/β-catenin pathway.Translational cancer research · 2021Article
- Emerging Insights on the Biological Impact of Extracellular Vesicle-Associated ncRNAs in Multiple Myeloma.Non-coding RNA · 2020Review
- Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.Bosnian journal of basic medical sciences · 2020Article
- MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6.Experimental and therapeutic medicine · 2019Article
- MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression.The Kaohsiung journal of medical sciences · 2019Article
- Identifying the optimal target genes associated with multiple myeloma by a novel bioinformatical analysis.Oncology letters · 2019Article
- The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma.Oncology letters · 2018Review
- MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.Current osteoporosis reports · 2017Review
- Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21.Journal of Cancer · 2017Article
- Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer.OncoTargets and therapy · 2017Review
- Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC.Frontiers in genetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a monoclonal malignant plasma cell disorder with an apparent homogeneity as opposed to leukemia and lymphomas. The recent introduction of thalidomide, lenalidomide and bortezomib has prolonged survival of patients with MM, and drug resistance or relapse of disease is perhaps still the major concern. Deregulation of hundreds of genes and multiple signaling pathways leads to MM pathogenesis and disease progression. While many of these genes and signaling pathways are regulated by microRNAs (miRNAs). miRNAs are small 19-22 nucleotide single-stranded RNAs that either as tumor suppressors or oncogenes play an important role in the progression and pathogenesis of cancer. Among them, microRNA-21 (miR-21) is frequently up-regulated in many cancers. Recent studies have shown that miR-21 displays an important role in the occurrence, development, recurrence and drug resistance of MM. In this review, we aim at summarizing the current knowledge of miR-21 functions in MM, with an emphasis on its laboratory research and clinical research in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.